Results 101 to 110 of about 5,574 (244)

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

Immunopharmacology 2020. V International Congress on Immunopharmacology

VacciMonitor, 2020
The Organizing Committee of the “V International Congress on Immunopharmacology” (Immunopharmacology 2020) organized by the Cuban Society of Pharmacology, BioCubaFarma and the International Union of Basic and Clinical Pharmacology (IUPHAR) would like to ...
Mario Landys Chovel Cuervo, Silvio Perea
doaj  

Biotech drugs : biological therapeutic agents [PDF]

, 2009
The recent years has seen significant growth in a new therapeutic approach to the management of disease. Biological therapeutic agents, constitute a broad category of drugs, usually generated by recombinant techniques from living organisms.
Fenech, Anthony G., Grech, Godfrey
core   +1 more source

Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes Network

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1156-1159, May 2026.
ASCPT has a mission to advance clinical pharmacology and translational sciences to reduce health disparities. The development, regulatory, and outcomes (DRO) network within ASCPT strives to advance pharmacoequity globally. Pharmacoequity, coined by Utibe Essien (2021), is the principle that all individuals, regardless of race, ethnicity, geography, or ...
Priya Jayachandran, Mayur K. Ladumor, Georgios Vlasakakis, Andrew Riselli, Katarina V. Ilic, Rob C. van Wijk, Mohamed Elmeliegy, Jatinder Kaur Mukker, Aarti Sawant‐Basak, Tao Long, Juyao Dong, Noha Rayad, Tao Zhang, on behalf of the DRO Network   +13 more
wiley   +1 more source

Clinical evidence and implementation guidance for biosimilar switching in ankylosing spondylitis

Frontiers in Pharmacology
Biosimilar tumor necrosis factor inhibitors provide therapeutically equivalent alternatives to reference biologics for ankylosing spondylitis (AS) management at reduced costs.
Luoyang Cai, Xin Chen, Yangbin Fang, Li Li, Tao Liu, Zhenkun Gan, Zheng Zuo   +6 more
doaj   +1 more source

Bioequivalence of HX575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple intravenous administrations: an open-label randomised controlled trial [PDF]

, 2009
Conclusions: HX575 and the comparator epoetin alfa were bioequivalent with respect to their PK/PD, supporting the conclusion that both, when administered subcutaneously, will be equally efficacious and may be interchangeable as therapy.
Fritz Sörgel, Ursula Thyroff-Friesinger, Andrea Vetter, Bernhard Vens-Cappell, Martina Kinzig   +4 more
core   +2 more sources

Advancing Pharmacometrics in Africa: Insights and Perspectives From the 2025 Pharmacometrics Africa Conference

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1216-1222, May 2026.
Pharmacometrics (PMX) in Africa has transitioned from foundational capacity‐building to job creation, scientific leadership, regulatory influence, and health innovation. To accelerate this progress, the 2025 Pharmacometrics Africa Conference (PMXAC‐2025) convened key stakeholders to consolidate the continental PMX community, review progress in local ...
Babatunde Ayodeji Adeagbo, Innocent Gerald Asiimwe, Linda Chaba, Aida N. Kawuma, Francis Williams Ojara, Ochuko Maureen Orherhe, Simon Peter Asiimwe, Veshni Pillay‐Fuentes Lorente, Sharon Sawe, Cassius M. Phogole, Catriona Waitt, Samer Mouksassi, Goonaseelan (Colin) Pillai   +12 more
wiley   +1 more source

The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review

Health Science Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed, Tasfiah Tasnim Maha, Sanjana Nowsher, Wasima Taslim, Fatema‐Tuz‐Zohora, Sabrina Sharmin, Hasina Yasmin   +6 more
wiley   +1 more source

The market of biopharmaceutical medicines: A snapshot of a diverse industrial landscape [PDF]

, 2017
Background: Biopharmaceutical medicines represent a growing share of the global pharmaceutical market, and with many of these biopharmaceutical products facing loss of exclusivity rights, also biosimilars may now enter the biopharmaceutical market ...
Declerck, P.J. (Paul), Huys, I. (Isabelle), Meuwissen, N. (Nicolas), Moorkens, E. (Evelien), Simoens, S. (Steven), Vulto, A.G. (Arnold)   +5 more
core   +4 more sources

Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter

Clinical Pharmacology & Therapeutics
There are no clinically meaningful differences between bio‐originators (BO) and their biosimilars (BS) in safety and efficacy. However, differences in pharmaceutical properties, such as volume and excipient, can occur. This study aimed to compare outcomes between patients transitioning from the modernized adalimumab BO (0.4 mL/no ...
Amy C.D. Peeters, Maike H.M. Wientjes, Wieland D. Müskens, David F. Ten Cate, Laura C. Coates, Bart J. F. van den Bemt, Noortje van Herwaarden, Alfons A. den Broeder   +7 more
openaire   +1 more source